An efficient strategy to access 3-amino-2H-indazoles starting from readily available 2-nitrobenzonitriles has been developed.
一种从易得的2-硝基苯腈出发制备3-氨基-2H-吲唑的高效策略已被开发。
[EN] BICYCLIC INHIBITORS OF ALK<br/>[FR] INHIBITEURS BICYCLIQUES DE L'ALK
申请人:ABBOTT LAB
公开号:WO2012097682A1
公开(公告)日:2012-07-26
The present invention relates to compounds of formula (1) or pharmaceutical acceptable salts, wherein R1, X, Y, Z, A, B, G1, and n are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as ALK and methods of treating diseases such as cancer.
Inhibitors of the Human Aldosterone Sythase CYP11B2
申请人:Hartmann Rolf W.
公开号:US20110112067A1
公开(公告)日:2011-05-12
The invention provides compounds of the general formula (I)
which are inhibitors of the human aldosterone synthase, and also pharmaceutical compositions containing these compounds, and a method of treating of hyperaldosteronism and/or disorders or diseases that are mediated by 11β-hydroxylase (CYP11B1) with these compounds.
A new and distinct cultivar of
Hydrangea
plant named ‘SCHROLL116-09-01a’, characterized by its compact, upright and mounded plant habit; moderately vigorous growth habit; freely branching habit and strong stems; large mophead-type inflorescences with light pink-colored sterile flowers that are initially greenish white in color during early development; long flowering period; and strong root system.
6-Pyridin-3-YL-3,4-Dihydro-1H-Quinolin-2-One Derivatives and Related Compounds as Inhibitors of the Human Aldosterone Synthase CYP11B2
申请人:Hartmann Rolf W.
公开号:US20110118241A1
公开(公告)日:2011-05-19
The invention provides compounds of the general formula (I) which are inhibitors of the human aldosterone synthase, and also pharmaceutical compositions containing these compounds, and the use of these compounds and other heteroaryl substituted quinolinone derivatives for the treatment of hyperaldosteronism and/or disorders or diseases that are mediated by 11 β-hydroxylase (CYP11 B1).